Category: Biotech Stocks

Moderna Inc. (NASDAQ: MRNA) has reported positive topline results from its pivotal Phase 3 P304 trial of mRNA-1010, its quadrivalent seasonal influenza vaccine candidate. Enrolling 40,805 adults aged 50 years and older across 11 countries, the observer-blind, active-controlled study demonstrated an overall 26.6 percent relative vaccine efficacy (rVE; 95 percent CI 16.7 percent–35.4 percent) versus […]

Tyson Foods, Inc. (NYSE:TSN) is a prominent player in the meat industry, contributing significantly to the nation’s beef, pork, and chicken supply. Through Tyson Ventures, the company has made strategic investments in emerging lab-grown meat startups like Memphis Meats (now UPSIDE Foods) and Future Meat Technologies (now Believer), positioning itself at the forefront of innovation […]

Joe Kiani, the visionary behind Masimo, has embarked on new ventures post his departure from the company. His latest project, Willow Laboratories, is dedicated to diabetes prevention through an innovative app. Additionally, Kiani has taken the helm as CEO of Like Minded Labs, a media company based in Santa Monica. Known for his association with […]

Ionis Pharmaceuticals stands at the forefront of innovative antisense technology, dedicated to the discovery and development of groundbreaking drugs across various therapeutic areas. With a robust clinical and preclinical pipeline, the company focuses on addressing a wide spectrum of diseases, particularly cardiovascular, metabolic, neurological, and rare conditions. Noteworthy achievements include the successful launch of Spinraza […]

Incyte is a biotech company known for its focus on the discovery and development of small-molecule drugs. Their flagship drug, Jakafi, has shown success in treating rare blood cancers and graft versus host disease, and is a result of a partnership with Novartis. With other marketed drugs like Olumiant, Iclusig, Pemazyre, Tabrecta, Monjuvi, and Opzelura, […]

Incyte Corporation (NASDAQ:INCY) made waves in the stock market as its shares soared 10.4% following the release of its second-quarter financial results. The biopharmaceutical company exceeded analyst expectations, reporting quarterly revenue of $1.22 billion, a 17.3% increase from the previous year. This impressive growth was driven by robust product sales, including an 8% increase in […]

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a leading biopharmaceutical technology platform company known for its development, manufacturing, and commercialization of innovative drug-device combination products utilizing advanced auto-injector technology. With a focus on enhancing patient comfort, adherence, tolerability, and convenience, Halozyme is at the forefront of revolutionizing the healthcare industry. Recently, Morgan Stanley analyst Sean Laaman provided […]

Galapagos NV recently released their half-year 2025 financial results and provided a detailed business update. The company’s CEO, Henry Gosebruch, expressed optimism about the future, emphasizing the focus on transformational transactions to enhance their pipeline and deliver impactful therapies to patients. With a strong balance sheet boasting €3.1 billion in cash and financial investments as […]

Exelixis Inc (NASDAQ:EXEL) continues to demonstrate impressive growth with their CABOMETYX franchise, as evidenced by their recent second-quarter 2025 financial results. CEO Michael Morrissey and EVP of Commercial Patrick Haley expressed confidence in sustaining market share gains for CABOMETYX, with a strong presence in renal cell carcinoma (RCC) and promising prospects in neuroendocrine tumors (NET). […]

Edwards Lifesciences’ stock experienced a significant surge following a stellar second-quarter 2025 earnings report. The medical device innovator exceeded revenue and earnings expectations, showcasing remarkable growth in its heart valve therapies. This exceptional performance led to an upward revision in the company’s full-year sales guidance, indicating a resurgence in its key markets. With sales growth […]

Celyad Oncology, a leading biotechnology company specializing in CAR-T technology, has recently announced a significant milestone in its financial strategy. The company has entered into a subscription agreement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, for a private placement financing of €1 million. This financing will result in the issuance of […]

Bristol-Myers Squibb Company (NYSE:BMY) is on the brink of releasing its quarterly results, with expectations running high for a mixed outcome. While positive impacts from foreign exchange rates may buoy earnings, concerns linger over potential negative effects from recent deals and challenges at the product level. Goldman Sachs analyst Asad Haider has maintained a Hold […]

In the dynamic world of finance, it is crucial for investors to stay informed about companies experiencing growth in their earnings estimates. The Progressive Corporation, a property-casualty insurance products and related services company, has seen an 8.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days. Similarly, BioNTech […]

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, has appointed Rajat Mehta as its new Executive Vice President, Global Commercial Operations. Mehta will lead Bio-Rad’s global commercial strategy and execution, bringing a proven track record of delivering above-market growth and building high-achieving teams. His appointment comes as a part of […]

Moderna, a leading biotech company, is making significant strides in the development of various pipeline candidates, including mRNA-1010, an influenza vaccine showing superior efficacy compared to a GSK flu shot. The company’s COVID-19 vaccine, Spikevax, continues to drive revenue, albeit with a projected decline due to lower demand. Additionally, Moderna’s RSV vaccine, mResvia, recently received […]

Celcuity Inc. experienced a significant increase in stock value following the release of positive findings from the Phase 3 VIKTORIA-1 trial. The trial focused on evaluating the effectiveness and safety of gedatolisib in combination with fulvestrant, with or without palbociclib, compared to fulvestrant alone. This study targeted patients with HR-positive/HER2-negative advanced breast cancer who had […]

Sanofi Energizes Immunology Research with a Colossal $9.5 Billion Acquisition of Blueprint In a bold and strategic move, France’s pharmaceutical giant, Sanofi, has announced its acquisition of Blueprint Medicines Corporation, a US-based biopharma group, for a staggering $9.5 billion. This acquisition propels Sanofi into the limelight of the biopharmaceutical sector, significantly bolstering its presence and […]